From MarketWatch:



2023 was a big year for obesity drugs in terms of investor gains, creating potential for scientific breakthroughs, corporate deal-making, and better patient access in 2024. Pharmaceutical giants Eli Lilly and Novo Nordisk were expected to lead the obesity-drug race, with the potential for more contenders to emerge. The market for these drugs was projected to grow to $100 billion over the next five to seven years. Potential for better insurance coverage and public understanding of obesity was expected in the coming year. In addition, there were five trends to watch in the obesity-drug world in 2024, including more wins for Lilly and Novo, the potential for more corporate deal-making, the challenges around developing pill versions of popular GLP-1 drugs, the development of drugs to preserve muscle, and improving insurance coverage and patient access.



Original: Five obesity-drug trends to watch in 2024